GenSight Biologics announced two key senior executive appointments. Philippe Motté has been named Senior Vice President, Regulatory and Quality reporting to Chief Executive Officer Bernard Gilly and a member of the Executive Committee, effective immediately. Philippe Motté will be responsible for ensuring consistency of activities in relation to regional and local regulatory authorities, coordinating teams to prepare for pre-marketing inspections of LUMEVOQ® and ensuring regulatory compliance in the future marketing of LUMEVOQ®.

He will report to Bernard Gilly as a member of the Executive Committee. Philippe holds a PharmD from the Paris-Descartes University and a PhD in Human Biology from the Paris-Sud University. He completed his Postdoctoral Fellowship at Harvard Medical School and the Massachusetts General Hospital Cancer Center, and he earned an MBA from the ESCP-EAP European School of Management (Paris).

He is certified as a Pharmacien Responsable (Responsible Pharmacist) in France and has been elected a member of the French National Academy of Pharmacy. Philippe is also Visiting Professor at University Paris-Saclay. He worked for many years in regulatory, quality and commercial roles in leading healthcare companies such as Sanofi (then as Pasteur-Mérieux), GSK (then as Smithkline-Beecham), Roche, Ipsen, Abbvie and Medday Pharmaceuticals.

He also founded the coaching and consulting firm Celestial Consulting & Coaching in the biotech and pharmaceutical sector. More recently, Philippe joins GenSight after serving as Chief Regulatory and Quality Officer at the biopharmaceutical company Genfit.